Dupilumab Reduces Caregiver Burden and Family Impact Among Caregivers of Pediatric Patients With Moderate-to-Severe Atopic Dermatitis in Clinical Practice: RELIEVE-AD-PED Study

Abstract

Introduction Treatment with dupilumab significantly reduced disease burden on caregivers and families of patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. This analysis evaluated dupilumab impact on caregiver burden among pediatric patients with moderate-to-severe AD based on interim data from a real-world study.

Methods RELIEVE-AD-PED is an ongoing, prospective, longitudinal survey study of pediatric patients aged 6m – 17y with moderate-to-severe AD who initiated dupilumab, and their caregivers, recruited from DUPIXENT MyWay®, a patient support program. Eligible pediatric patients from USA and their caregivers completed surveys at baseline and at multiple time points after dupilumab initiation. The impact of AD on caregivers was evaluated with the Dermatitis Family Impact questionnaire (DFI; range 0–30; higher scores indicate greater impact) and a stand-alone question assessing if the caregiver experienced sleep problems because of their child’s AD (with a 1-week recall period). Here, we report data up to Month 6 for the 6m – 5y age group and to Month 12 for the 6–17y group.

Results 696 caregivers of pediatric patients with AD (238 caregivers of patients aged 6m – 5y; 197 caregivers of 6–11-year-olds; and 261 caregivers of 12–17-year-olds) who initiated dupilumab treatment completed baseline surveys.

Mean (SD) DFI score significantly decreased from baseline (12.9 [7.4], 11.6 [6.8], and 9.3 [6.6] for caregivers of patients aged 6m – 5y, 6–11y, and 12–17y, respectively) to Month 1 (5.1 [5.9], 3.8 [4.4], and 3.6 [4.7]). DFI scores reduction from baseline were maintained at Month 6 for the caregivers of the 6m – 5y group (mean [SD] of 5.1 [6.4]) and at Month 12 for the 6–11y and 12–17y groups (3.3 [4.8] and 2.5 [4.0]). The proportion of caregivers reporting a normal quality-of-life (QoL; DFI score 0–5) significantly increased from baseline (16.0%, 18.8%, and 33.7% of caregivers of patients aged 6m – 5y, 6–11y, and 12–17y) to Month 1 (64.3%, 75.2%, and 77.2%). This increase was sustained at Month 6 for the 6m – 5y group (61.7%) and at Month 12 for the 6–11y and 12–17y groups (81.4% and 84.6%).

The proportion of caregivers reporting sleep problems due to their child’s AD significantly decreased from baseline (76.1%, 62.4%, and 31.0% of caregivers of patients aged 6m – 5y, 6–11y, and 12–17y) to Month 1 (38.3%, 19.0%, and 7.6%). This reduction was sustained at Month 6 for the 6m – 5y group (33.3%) and at Month 12 for the 6–11y and 12–17y groups (14.0% and 9.9%).

All post-treatment time points were significantly improved from baseline (P<0.001).

Conclusions Dupilumab led to a reduction in the caregiver burden and family impact of AD as early as Month 1 in families of pediatric patients with moderate-to-severe AD, accompanied by improved QoL and sleep, all of which were sustained to Month 6 for the 6m – 5y age group and to Month 12 for the 6–17y group in a real-world study.